BBNX Deadline: Beta Bionics Investors Should Contact Block & Leviton Before November 3rd

Boston, Massachusetts--(Newsfile Corp. - October 26, 2026) - Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its executives. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bbnx.

According to the complaint, Beta Bionics and certain of its executives misled investors about the safety of the company's sole commercial product, the iLet Bionic Pancreas automated insulin pump. The complaint alleges that after receiving an FDA Form 483 in mid-2025 that documented more than 18,000 unreported customer complaints across fewer than 30,000 iLet users — including hundreds of life-threatening hypoglycemic events — the company repeatedly told investors the FDA's concerns were "a very benign issue" limited to how complaints were categorized and had "nothing to do with the actual complaints being received or the number of them," while continuing to tout the device's clinical outcomes. The truth allegedly emerged through a series of disclosures beginning January 8, 2026, when a miss on new patient starts sent the stock down roughly 37% in a single day, followed by investigative reports and the company's January 30, 2026 disclosure of an FDA warning letter, and culminating on February 24, 2026, when the FDA publicly released its warning letter directly contradicting management's characterization. The complaint alleges the stock fell from $31.99 to under $13 per share over this period. Investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 may have legal rights.